Alder rises on Phase IIb chronic migraine data

Alder Biopharmaceuticals Inc. (NASDAQ:ALDR) gained $8.52 (50%) to $25.70 on Monday after reporting that two doses of IV ALD403 met the primary endpoint in a Phase IIb trial to prevent chronic migraine.

The calcitonin gene-related peptide

Read the full 369 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE